Overview
The marketing authorisation for Zulvac 1 Bovis has been withdrawn at the request of the marketing authorisation holder.
Zulvac 1 Bovis : EPAR - Summary for the public
English (EN)
(222.99 KB - PDF)View
български (BG)
(509.58 KB - PDF)
español (ES)
(384.95 KB - PDF)
čeština (CS)
(451.17 KB - PDF)
dansk (DA)
(381.07 KB - PDF)
Deutsch (DE)
(409.83 KB - PDF)
eesti keel (ET)
(379.73 KB - PDF)
ελληνικά (EL)
(514.35 KB - PDF)
français (FR)
(409.54 KB - PDF)
italiano (IT)
(408.74 KB - PDF)
latviešu valoda (LV)
(471.49 KB - PDF)
lietuvių kalba (LT)
(435.02 KB - PDF)
magyar (HU)
(456.96 KB - PDF)
Malti (MT)
(438.24 KB - PDF)
Nederlands (NL)
(385.42 KB - PDF)
polski (PL)
(464.22 KB - PDF)
português (PT)
(408.96 KB - PDF)
română (RO)
(415.31 KB - PDF)
slovenčina (SK)
(436.84 KB - PDF)
slovenščina (SL)
(455.38 KB - PDF)
Suomi (FI)
(403.39 KB - PDF)
svenska (SV)
(384.08 KB - PDF)
Product information
Zulvac 1 Bovis : EPAR - Product information
English (EN)
(369.04 KB - PDF)View
български (BG)
(735.77 KB - PDF)
español (ES)
(588.23 KB - PDF)
čeština (CS)
(780.58 KB - PDF)
dansk (DA)
(591.89 KB - PDF)
Deutsch (DE)
(573.04 KB - PDF)
eesti keel (ET)
(586.69 KB - PDF)
ελληνικά (EL)
(905.3 KB - PDF)
français (FR)
(614.9 KB - PDF)
hrvatski (HR)
(652.84 KB - PDF)
íslenska (IS)
(595.81 KB - PDF)
italiano (IT)
(604.98 KB - PDF)
latviešu valoda (LV)
(807.34 KB - PDF)
lietuvių kalba (LT)
(651.56 KB - PDF)
magyar (HU)
(796.39 KB - PDF)
Malti (MT)
(798.16 KB - PDF)
Nederlands (NL)
(607.21 KB - PDF)
norsk (NO)
(604.74 KB - PDF)
polski (PL)
(780.98 KB - PDF)
português (PT)
(603.86 KB - PDF)
română (RO)
(667.48 KB - PDF)
slovenčina (SK)
(811.09 KB - PDF)
slovenščina (SL)
(776.57 KB - PDF)
Suomi (FI)
(586.27 KB - PDF)
svenska (SV)
(591.79 KB - PDF)
Latest procedure affecting product information: IB/00017
21/06/2019
Zulvac 1 Bovis : EPAR - All authorised presentations
English (EN)
(188.13 KB - PDF)View
български (BG)
(230.28 KB - PDF)
español (ES)
(343.83 KB - PDF)
čeština (CS)
(369.47 KB - PDF)
dansk (DA)
(347.52 KB - PDF)
Deutsch (DE)
(348.53 KB - PDF)
eesti keel (ET)
(355.15 KB - PDF)
ελληνικά (EL)
(383.16 KB - PDF)
français (FR)
(344.14 KB - PDF)
hrvatski (HR)
(356.23 KB - PDF)
íslenska (IS)
(322.68 KB - PDF)
italiano (IT)
(357.42 KB - PDF)
latviešu valoda (LV)
(383.76 KB - PDF)
lietuvių kalba (LT)
(373.86 KB - PDF)
magyar (HU)
(368 KB - PDF)
Malti (MT)
(387.39 KB - PDF)
Nederlands (NL)
(347.91 KB - PDF)
norsk (NO)
(343.71 KB - PDF)
polski (PL)
(386.15 KB - PDF)
português (PT)
(356.42 KB - PDF)
română (RO)
(360.37 KB - PDF)
slovenčina (SK)
(371.83 KB - PDF)
slovenščina (SL)
(382.39 KB - PDF)
Suomi (FI)
(346.35 KB - PDF)
svenska (SV)
(359.59 KB - PDF)
Product details
- Name of medicine
- Zulvac 1 Bovis
- Active substance
- inactivated bluetongue virus, serotype 1
- International non-proprietary name (INN) or common name
- inactivated bluetongue virus, serotype 1
- Species
- Cattle
- Anatomical therapeutic chemical veterinary (ATCvet) code
- QI02AA08
Pharmacotherapeutic group
ImmunologicalsTherapeutic indication
Active immunisation of cattle from 2½ months of age for the prevention of viraemia caused by bluetongue virus, serotype 1.
Onset of immunity: 15 days after completion of the primary vaccination course.
Duration of immunity: 12 months.
Assessment history
This page was last updated on